AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3435691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol
Number of subjects: 5
Study 29206720 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention providing 80% reduction in susceptibility per act; specific dosage and duration not mentioned.
Number of subjects: 0
Study 28770449 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU oral VitD3/week
Number of subjects: 160
Study 28770449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26791798 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed + cisplatin (500 mg/m² + 75 mg/m²)
Number of subjects: 122
Study 26791798 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed + carboplatin (500 mg/m² + AUC5)
Number of subjects: 122
Study 23716291 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCT‐CA evaluation by trainee radiologists at baseline, 4 weeks, 8 weeks, and 6 months
Number of subjects: 3
Study 22024529 — intervention group
Group type: EXPERIMENTAL
Intervention: Opened capsule dosing method (30 mg)
Number of subjects: 28
Study 22024529 — intervention group
Group type: COMPARATOR
Intervention: Intact capsule dosing method (30 mg)
Number of subjects: 28
Study 18208955 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior vena cava (IVC) filters
Number of subjects: 0
Study 18208955 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable IVC filters
Number of subjects: 0
Study 16390470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral lubricating device
Number of subjects: 29
Study 13678775 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg i.v. neridronate bimonthly and 500 mg calcium plus 400 U vitamin D supplements daily (n=39)
Number of subjects: 78
Study 13678775 — intervention group
Group type: COMPARATOR
Intervention: Calcium-vitamin D supplements alone (control group, n=39)
Number of subjects: 78
Study 10916115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/day (group A)
Number of subjects: 57
Study 10916115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 57
Study 8956382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg/day or 5 mg/day
Number of subjects: 423
Study 8956382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 1388038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg/day plus hydration
Number of subjects: 44
Study 1388038 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hydration
Number of subjects: 44
Study 3894196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI)
Number of subjects: 17
Study 3894196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3894196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) after placebo
Number of subjects: 17
Study 31413163 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored self-management intervention (n=102)
Number of subjects: 201
Study 31413163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) (n=99)
Number of subjects: 201
Study 29167117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity one-legged cycling (HIC; 8 × 4 at 90% one-legged cycling max)
Number of subjects: 8
Study 29167117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity one-legged cycling (HIC)
Number of subjects: 8
Study 29167117 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 8
Study 27482970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg esmirtazapine
Number of subjects: 0
Study 27482970 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg esmirtazapine
Number of subjects: 0
Study 27482970 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg esmirtazapine
Number of subjects: 0
Study 27482970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25386752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block with ropivacaine
Number of subjects: 36
Study 25386752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36
Study 22486948 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D(3)
Number of subjects: 89
Study 22486948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 20391060 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman-Focused intervention
Number of subjects: 0
Study 20391060 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study 17908411 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ovarian drilling
Number of subjects: 87
Study 17908411 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ovarian drilling
Number of subjects: 87
Study 16240844 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet intervention
Number of subjects: 104
Study 11950006 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncaria tomentosa (UT) extract
Number of subjects: 40
Study 11950006 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncaria tomentosa (UT) extract during second phase
Number of subjects: 40
Study 11950006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10023788 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 0
Study 7599664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of human menopausal gonadotropin (hMG) 150 IU
Number of subjects: 6
Study 7599664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of human menopausal gonadotropin (hMG) 150 IU
Number of subjects: 6
Study 2240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 2240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30
Study 2240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 912132 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitrogen mustard with and without tolerance induction
Number of subjects: 0
Study 912132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0
Study 912132 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA in combination with Cyclophosphamide
Number of subjects: 0
Study 912132 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin and Methotrexate
Number of subjects: 0
Study 30986736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy with integrated elements of emotion‐focused therapy (CBT + EFT)
Number of subjects: 47
Study 30986736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy with treatment components based on self‐regulation theory (CBT + SR)
Number of subjects: 47
Study 30986736 — intervention group
Group type: COMPARATOR
Intervention: Patients diagnosed with anxiety disorders
Number of subjects: 47
Study 30986736 — intervention group
Group type: COMPARATOR
Intervention: Patients diagnosed with depression
Number of subjects: 47
Study 28339547 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Programme 10-14 (SFP10-14)
Number of subjects: 614
Study 28339547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 614
Study 25929897 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation (28 capsules over 14 days, twice a day)
Number of subjects: 650
Study 25929897 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (matching to probiotic preparation)
Number of subjects: 650
Study 25929897 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 650
Study 25929897 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 650
Study 23587104 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered structured questionnaire assessing sexual health knowledge
Number of subjects: 419
Study 23587104 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants for poor sexual health education in ≤15 years
Number of subjects: 419
Study 23587104 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants for poor sexual health knowledge in >15 years
Number of subjects: 419
Study 21278102 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable reminders for screening mammography
Number of subjects: 228
Study 21278102 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable reminders for bone-density exams
Number of subjects: 228
Study 21278102 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable reminders for HbA1c monitoring
Number of subjects: 228
Study 21278102 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable reminders for LDL cholesterol monitoring
Number of subjects: 228
Study 21278102 — intervention group
Group type: COMPARATOR
Intervention: Actionable reminders
Number of subjects: 228
Study 19899003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT) - 57 Gy in 17 fractions (13 fractions of 3 Gy plus 4 fractions of 4.5 Gy)
Number of subjects: 91
Study 19899003 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 74 Gy in 37 fractions at 2 Gy per fraction for 7.5 weeks
Number of subjects: 91
Study 17103172 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment group
Number of subjects: 0
Study 17103172 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate disease activity group
Number of subjects: 0
Study 15521667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amphotericin B and endoscopic surgery, associated or not with Caldwell‐Luc surgery
Number of subjects: 11
Study 15521667 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 11
Study 12618641 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized targeted mailing encouraging mammogram screening
Number of subjects: 2458
Study 12618641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mailing)
Number of subjects: 2458
Study 12618641 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized targeted mailing
Number of subjects: 2458
Study 10214835 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg intravaginally every 6 hours
Number of subjects: 100
Study 10214835 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 microg intravaginally every 12 hours
Number of subjects: 100
Study 8675722 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report diagnostic measure of GAD based on DSM criteria
Number of subjects: 2
Study 8675722 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report diagnostic measure of GAD
Number of subjects: 2
Study 2224121 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via intravenous (IV) bolus
Number of subjects: 10
Study 2224121 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via subcutaneous (SC) injection
Number of subjects: 10
Study 2224121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 78095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 43
Study 78095 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study 78095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment for first 4 years, followed by withdrawal
Number of subjects: 43
Study 78095 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen treatment (first 4 years) vs. Placebo (full 8 years)
Number of subjects: 43
Study 31277052 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program educational intervention (curriculum-based, over 2 or 4 academic years)
Number of subjects: 1326
Study 31277052 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 1326
Study 31277052 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program educational intervention
Number of subjects: 1326
Study 27470122 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced messaging emphasizing safe sleep practices, including avoidance of bedsharing for both SIDS risk reduction and suffocation prevention.
Number of subjects: 1194
Study 27470122 — intervention group
Group type: COMPARATOR
Intervention: Standard messaging emphasizing AAP-recommended safe sleep practices, including avoidance of bedsharing for SIDS risk reduction.
Number of subjects: 1194
Study 27470122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (enhanced and standard messaging)
Number of subjects: 1194
Study 25575940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.)
Number of subjects: 1055
Study 25575940 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (100, 250 or 500 μg b.i.d.)
Number of subjects: 1055
Study 23070786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group psychotherapy plus open methylphenidate treatment
Number of subjects: 144
Study 23070786 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 144
Study 21332722 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplas LG
Number of subjects: 30
Study 21332722 — intervention group
Group type: COMPARATOR
Intervention: Octaplas LG
Number of subjects: 30
Study 21332722 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplas LG and Octaplas LG
Number of subjects: 30
Study 19101236 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-CKD
Number of subjects: 2218
Study 19101236 — intervention group
Group type: COMPARATOR
Intervention: DM-only
Number of subjects: 2218
Study 17519315 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (SD)
Number of subjects: 10
Study 15177608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 20
Study 15177608 — intervention group
Group type: EXPERIMENTAL
Intervention: Moria M2 microkeratome
Number of subjects: 20
Study 15177608 — intervention group
Group type: COMPARATOR
Intervention: Bausch & Lomb Automated Corneal Shaper (ACS) microkeratome
Number of subjects: 20
Study 11475711 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips/Jordan HP735 powered toothbrush
Number of subjects: 3
Study 11475711 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun/Oral-B D7 powered toothbrush
Number of subjects: 3
Study 11475711 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Advantage B35 manual toothbrush
Number of subjects: 3
Study 9924264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread
Number of subjects: 12
Study 9924264 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 12
Study 7999481 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative caudal block
Number of subjects: 25
Study 7999481 — intervention group
Group type: COMPARATOR
Intervention: Postoperative caudal block
Number of subjects: 25
Study 31426772 — intervention group
Group type: EXPERIMENTAL
Intervention: Online patient decision aid (pDA)
Number of subjects: 0
Study 31426772 — intervention group
Group type: COMPARATOR
Intervention: Control group (information leaflet)
Number of subjects: 0
Study 27879044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) - dose-2 (640 mg phenolics/day)
Number of subjects: 49
Study 24958282 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-damaging agents
Number of subjects: 243
Study 24958282 — intervention group
Group type: EXPERIMENTAL
Intervention: p53-positive tumors
Number of subjects: 243
Study 24958282 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete SNP panel
Number of subjects: 243
Study 24958282 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH1C genotype and p53 status
Number of subjects: 243
Study 23915589 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB), n = 220
Number of subjects: 458
Study 23915589 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG (ONCAB), n = 238
Number of subjects: 458
Study 23915589 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 458
Study 21909836 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum heat shock protein 27 (sHSP27) levels
Number of subjects: 119
Study 19833904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 1895
Study 19833904 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 1895
Study 16157438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional matrix system with separation rings
Number of subjects: 71
Study 16157438 — intervention group
Group type: COMPARATOR
Intervention: Circumferential matrix system
Number of subjects: 71
Study 15572639 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer Assisted Self-Interview (ACASI)
Number of subjects: 700
Study 15572639 — intervention group
Group type: COMPARATOR
Intervention: Interviewer administered mode (Control)
Number of subjects: 700
Study 15572639 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 700
Study 11920175 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront ASCT
Number of subjects: 46
Study 11920175 — intervention group
Group type: COMPARATOR
Intervention: Delayed ASCT
Number of subjects: 46
Study 9055142 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg orally twice daily for 7 days)
Number of subjects: 0
Study 9055142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching oral doses for 7 days)
Number of subjects: 0
Study 8368982 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.10% BAL)
Number of subjects: 28
Study 8368982 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 28
Study 8368982 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.10% BAL to 8 hours)
Number of subjects: 28
Study 8368982 — intervention group
Group type: EXPERIMENTAL
Intervention: Older pilots
Number of subjects: 28
Study 3463349 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Drinking (CD)
Number of subjects: 46
Study 3463349 — intervention group
Group type: COMPARATOR
Intervention: Abstinence (ABST)
Number of subjects: 46
Study 31216537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tolvaptan and reduced furosemide doses)
Number of subjects: 29
Study 31216537 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (original furosemide dosage)
Number of subjects: 29
Study 30216917 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate, fixed dose
Number of subjects: 602
Study 26935057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B (CpG)
Number of subjects: 28
Study 26935057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B (CpG) + GM-CSF (GM)
Number of subjects: 28
Study 26935057 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28
Study 26935057 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG + GM
Number of subjects: 28
Study 26935057 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG
Number of subjects: 28
Study 25264862 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAY Project Home Consultation model
Number of subjects: 128
Study 25264862 — intervention group
Group type: COMPARATOR
Intervention: Usual community services (CS) only
Number of subjects: 128
Study 22706128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 million stem cells (group A)
Number of subjects: 200
Study 22706128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 million adipose-derived stem cells plus fibrin glue (group B)
Number of subjects: 200
Study 22706128 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue (group C)
Number of subjects: 200
Study 20150394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation A
Number of subjects: 23
Study 20150394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation B
Number of subjects: 23
Study 20150394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation C
Number of subjects: 23
Study 20150394 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (20 mg/kg)
Number of subjects: 23
Study 20150394 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (50 mg/kg)
Number of subjects: 23
Study 20150394 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (100 mg/kg)
Number of subjects: 23
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + rifampicin 600 mg q.d.
Number of subjects: 72
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + efavirenz (EFV) 600 mg q.d.
Number of subjects: 72
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 200 mg b.i.d. + rifampicin or EFV
Number of subjects: 72
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg b.i.d. + LPV/r (lopinavir 400 mg + ritonavir 100 mg)
Number of subjects: 72
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + SQV/r (saquinavir 1000 mg + ritonavir 100 mg)
Number of subjects: 72
Study 18333864 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc + PI regimens with EFV
Number of subjects: 72
Study 18333864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16078219 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa administration
Number of subjects: 9
Study 16078219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9
Study 16689221 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation and thickness mapping of articular cartilage using MR images
Number of subjects: 3
Study 16689221 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-based assessment of tissue engineered grafts
Number of subjects: 3
Study 16689221 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of bovine and porcine cadaveric knees with artificial cartilage lesions
Number of subjects: 3
Study 10412882 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg OD
Number of subjects: 0
Study 10412882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0